Carcinoembryonic Antigen Market to hit $2.7bn by 2023: Global Market Insights, Inc. Ocean View, Delaware, April 20, 2017 (GLOBE NEWSWIRE) -- The research report “Carcinoembryonic Antigen (CEA) Market Size By Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer),...

Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer TUSTIN, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...

VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042)60% (9 of 15) durable response rate (as measured by...

Carcinoembryonic antigen (CEA) market size worth $2.78 Billion by 2023: Global Market Insights Inc. Dover, DE, May 16, 2016 (GLOBE NEWSWIRE) -- Carcinoembryonic antigen (CEA) market size is forecast to reach USD 2.78 billion by 2023; as reported in the latest study by Global Market Insights,...